Connect with us

Hi, what are you looking for?

Monday, Mar 4, 2024
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.


MGC Pharma gets permission from Slovenian health authorities to research psilocybin

MGC says it is the first company operating in Slovenia to obtain permission to engage in studies on the psychedelic compound

MGC Pharma gets permission from Slovenian health authorities to research psilocybin
Photo by 24-K Production via Shutterstock

United Kingdom-based MGC Pharmaceuticals Ltd (ASX: MXC) (LSE: MXC) has obtained permission from the Slovenian Ministry of Health to engage in research with psilocybin and says it is the first company operating in Slovenia to do so.

MGC announced the development on Monday and plans to develop new drug formulations with the psychedelic compound at its Slovenian research and development facility.

The company says it will now be able to bring the psychedelics industry one step closer to the pharmaceutical industry in Slovenia through the development of new psilocybin-based medicines. The company’s Chief Commercial Officer Robert Clements spoke about the news in an interview with Proactive Investors.

Read more: Dutch government establishes MDMA research commission

Read more: Psilocybin access denied to patients despite ongoing lawsuit against Health Canada

“We are pleased to have obtained permission from the Slovenian Ministry of Health to undertake pharmaceutical research with psilocybin, which puts the company at the forefront of experimental, pharmaceutical research,” said Roby Zomer, CEO and Managing Director of the company.

“We are extremely grateful to the Slovenian health ministry for enabling us to utilize our research expertise in this area,” he added.

MGC has a significant patient base in Australia where psilocybin will be a prescribable treatment for certain mental health conditions as of July this year.

MGC’s stock rose by 10 per cent on Wednesday to AUD$0.011 on the Australian Securities Exchange.

Europe and the U.K. have been key contributors to the psychedelics landscape in recent days

Last month, the federal government in the Netherlands established a research commission to study MDMA and its potential therapeutic uses. The commission will be presenting the findings from its multidisciplinary assessment to the Dutch Cabinet by the end of January next year.

In February, the United Kingdom’s Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) signed an agreement with an anonymous party to help establish a series of psychedelics clinics in Portugal.

An anonymous client in the U.K. has received or will soon be receiving a large shipment of MDMA (300 grams) from Canada’s PharmAla Biotech Holdings Inc. (CSE: MDMA) for research purposes.

Read more: Awakn Life Sciences helps establish psychedelics clinics in Portugal

Read more: PharmAla Biotech gets Health Canada approval to export large MDMA shipment to the U.K.

In November 2022, Australia’s Enosis Therapeutics partnered with Germany’s Ovid Clinics to offer virtual reality-modulated psychedelic therapy in Berlin.

In June last year, the Psychedelic Access and Research European Alliance was formed, comprising 16 different member organizations dedicated to progressing psychedelics science and research. Founding members included the Osmond Foundation, the European Brain Council and the Association of European Cancer Leagues.

Later in October 2022, the European Psychiatric Association joined PAREA as well. The EPA is the foremost association representing psychiatry in Europe and has more than 78,000 members.


Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Follow Rowan Dunne on Twitter









Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Medical and Pharmaceutical

Sovereign wealth funds Temasek and Mubadala engage in discussions to finance biotech ventures


Legislation anticipates federal legalization, establishes the Alaska Mental Health and Psychedelics Medicine Task Force


Mind Medicine Australia legally dosed the first patients outside of clinical trials in over 50 years last month

Health & Wellness

Partnership signals a milestone agreement for innovative treatment solutions